Document is current
Any future updates will be listed below
-
Authors
Pinter, Andreas
Galván, Jordi
Freischläger, Frank
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03308799 at ClinicalTrials.govnct03802344 at ClinicalTrials.govDocuments that mention this clinical trial
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials
https://doi.org/10.1007/s13555-025-01418-x
Documents that mention this clinical trial
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials
https://doi.org/10.1007/s13555-025-01418-x
Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application
https://doi.org/10.1007/s13555-022-00794-y
-
Funding
Funding for this research was provided by:
Almirall
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 8 April 2025
First Online: 24 April 2025
Declarations
:
: Andreas Pinter has no conflicts of interest to declare. Jordi Galván is an employee of Almirall S.A. Frank Freischläger is co-founder and co-owner of Estimondo GmbH.
: The study protocols of the two phase 3 studies were reviewed and approved by local institutional review boards or ethics committees (central institutional review board for trial MC2-01-C2: Quorum, 1501 Fourth Ave, Ste 800, Seattle, WA 98101; independent ethics committee for trial MC2-01-C7: Ethikkommission der Ärztekammer, Hamburg, Weidestraße 122b, 22083 Hamburg, Germany). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided written informed to participate in the phase 3 studies.
